1. Home
  2. KTF vs IMNM Comparison

KTF vs IMNM Comparison

Compare KTF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DWS Municipal Income Trust

KTF

DWS Municipal Income Trust

N/A

Current Price

$8.46

Market Cap

361.2M

Sector

Finance

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$23.86

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KTF
IMNM
Founded
1988
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
361.2M
2.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KTF
IMNM
Price
$8.46
$23.86
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$32.80
AVG Volume (30 Days)
168.9K
847.7K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
3.54%
N/A
EPS Growth
N/A
51.40
EPS
0.39
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
$21.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.45
$8.93
52 Week High
$9.37
$30.06

Technical Indicators

Market Signals
Indicator
KTF
IMNM
Relative Strength Index (RSI) 17.14 39.68
Support Level N/A $23.67
Resistance Level $9.25 $25.07
Average True Range (ATR) 0.06 1.00
MACD -0.03 -0.54
Stochastic Oscillator 2.31 15.53

Price Performance

Historical Comparison
KTF
IMNM

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: